Clinicopathologic and Prognostic Significance of Transducin-Like Enhancer of Split 1 Protein Expression in Invasive Breast Cancer.
- Author:
Ji Hye LEE
1
;
Sang Byung BAE
;
Mee Hye OH
;
Hyun Deuk CHO
;
Si Hyong JANG
;
Soon Auck HONG
;
Junhun CHO
;
Sung Yong KIM
;
Sun Wook HAN
;
Jong Eun LEE
;
Han Jo KIM
;
Hyun Ju LEE
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Immunohistochemistry; Prognosis; TLE1 protein; human
- MeSH: Breast Neoplasms*; Breast*; Carcinoma, Intraductal, Noninfiltrating; Co-Repressor Proteins; Disease-Free Survival; Estrogens; Humans; Immunohistochemistry; Lymph Nodes; Neoplasm Metastasis; Prognosis; Receptor, Epidermal Growth Factor; Receptors, Progesterone; Triple Negative Breast Neoplasms
- From:Journal of Breast Cancer 2017;20(1):45-53
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Transducin-like enhancer of split 1 (TLE1) is a member of the TLE family of transcriptional co-repressors that control the transcription of a wide range of genes. We investigated the prognostic significance of TLE1 protein expression in breast cancers by using immunohistochemistry and explored the relationship of TLE1 with clinicopathological parameters. METHODS: Immunohistochemistry was performed on 456 cases of breast cancer tiled on tissue microarrays. The relationship between TLE1 expression in normal breast specimens and ductal carcinoma in situ (DCIS) was also analyzed. RESULTS: TLE1 was highly expressed in 57 of 456 (12.5%) carcinoma samples. TLE1 was more frequently expressed in DCIS and invasive breast cancers than in normal breast tissue (p=0.002). High expression of TLE1 significantly correlated with negative lymph node (LN) metastasis (p=0.007), high histologic grade (p<0.001), estrogen receptor negativity (p<0.001), progesterone receptor negativity (p<0.001), human epidermal growth factor receptor 2 (HER2) positivity (p<0.001), and high Ki-67 proliferation index (p<0.001). Based on intrinsic subtypes, high TLE1 expression was strongly associated with HER2+ and triple-negative breast cancers (TNBC) (p<0.001). Survival analysis demonstrated no significant association between TLE1 expression and disease-free survival (DFS) (p=0.167) or overall survival (OS) (p=0.286). In subgroup analyses, no correlation was found between TLE1 expression and DFS or OS according to LN status or intrinsic subtype. CONCLUSION: High TLE1 expression is significantly associated with the HER2+ and TNBC subtypes. This is the first study documenting immunohistochemical expression of TLE1 in invasive breast cancer and its association with clinicopathological parameters, prognosis, and intrinsic subtype.
